{"uri": "eng-9423655", "concepts": [{"uri": "http://en.wikipedia.org/wiki/Narcolepsy", "type": "wiki", "score": 100, "label": {"eng": "Narcolepsy"}}, {"uri": "http://en.wikipedia.org/wiki/Cataplexy", "type": "wiki", "score": 90, "label": {"eng": "Cataplexy"}}, {"uri": "http://en.wikipedia.org/wiki/Placebo", "type": "wiki", "score": 74, "label": {"eng": "Placebo"}}, {"uri": "http://en.wikipedia.org/wiki/Excessive_daytime_sleepiness", "type": "wiki", "score": 62, "label": {"eng": "Excessive daytime sleepiness"}}, {"uri": "http://en.wikipedia.org/wiki/Cognition", "type": "wiki", "score": 44, "label": {"eng": "Cognition"}}, {"uri": "http://en.wikipedia.org/wiki/Remission_(medicine)", "type": "wiki", "score": 37, "label": {"eng": "Remission (medicine)"}}, {"uri": "http://en.wikipedia.org/wiki/Statistical_significance", "type": "wiki", "score": 37, "label": {"eng": "Statistical significance"}}, {"uri": "http://en.wikipedia.org/wiki/Quality_of_life", "type": "wiki", "score": 32, "label": {"eng": "Quality of life"}}, {"uri": "http://en.wikipedia.org/wiki/Central_nervous_system", "type": "wiki", "score": 31, "label": {"eng": "Central nervous system"}}, {"uri": "http://en.wikipedia.org/wiki/Adverse_event", "type": "wiki", "score": 30, "label": {"eng": "Adverse event"}}, {"uri": "http://en.wikipedia.org/wiki/Sleep_disorder", "type": "wiki", "score": 27, "label": {"eng": "Sleep disorder"}}, {"uri": "http://en.wikipedia.org/wiki/Biopharmaceutical", "type": "wiki", "score": 26, "label": {"eng": "Biopharmaceutical"}}, {"uri": "http://en.wikipedia.org/wiki/Reboxetine", "type": "wiki", "score": 26, "label": {"eng": "Reboxetine"}}, {"uri": "http://en.wikipedia.org/wiki/Depression_(mood)", "type": "wiki", "score": 25, "label": {"eng": "Depression (mood)"}}, {"uri": "http://en.wikipedia.org/wiki/Anxiety", "type": "wiki", "score": 25, "label": {"eng": "Anxiety"}}, {"uri": "http://en.wikipedia.org/wiki/Dopamine", "type": "wiki", "score": 24, "label": {"eng": "Dopamine"}}, {"uri": "http://en.wikipedia.org/wiki/Cerebral_cortex", "type": "wiki", "score": 24, "label": {"eng": "Cerebral cortex"}}, {"uri": "http://en.wikipedia.org/wiki/Neurology", "type": "wiki", "score": 22, "label": {"eng": "Neurology"}}, {"uri": "http://en.wikipedia.org/wiki/Food_and_Drug_Administration", "type": "wiki", "score": 21, "label": {"eng": "Food and Drug Administration"}}, {"uri": "http://en.wikipedia.org/wiki/Comorbidity", "type": "wiki", "score": 20, "label": {"eng": "Comorbidity"}}], "eventDate": "2024-03-25", "totalArticleCount": 11, "title": {"eng": "AXS-12 shows promise in narcolepsy treatment, trial finds By Investing.com"}, "summary": {"eng": "NEW YORK - Axsome Therapeutics, Inc. (NASDAQ: NASDAQ:AXSM), a biopharmaceutical company, announced today positive results from its Phase 3 SYMPHONY trial, indicating that its investigational drug AXS-12 (reboxetine) significantly reduced narcolepsy symptoms, including cataplexy attacks and excessive daytime sleepiness (EDS), compared to a placebo.\n\nThe SYMPHONY trial, which spanned multiple centers and was double-blind and placebo-controlled, enrolled 90 patients diagnosed with narcolepsy. Over f"}, "location": null, "categories": [{"uri": "dmoz/Health/Conditions_and_Diseases/Cardiovascular_Disorders", "label": "dmoz/Health/Conditions and Diseases/Cardiovascular Disorders", "wgt": 100}, {"uri": "dmoz/Health/Men's_Health/Conditions_and_Diseases", "label": "dmoz/Health/Men's Health/Conditions and Diseases", "wgt": 100}, {"uri": "dmoz/Health/Dentistry/Conditions_and_Diseases", "label": "dmoz/Health/Dentistry/Conditions and Diseases", "wgt": 77}, {"uri": "news/Health", "label": "news/Health", "wgt": 69}], "articleCounts": {"eng": 11}, "sentiment": 0.06666666666666665, "wgt": 449020800, "relevance": 2}